Share on StockTwits

Regulus Therapeutics (NASDAQ:RGLS) Insider Neil W. Gibson sold 4,479 shares of the stock on the open market in a transaction dated Friday, January 17th. The stock was sold at an average price of $8.15, for a total value of $36,503.85. Following the completion of the transaction, the insider now directly owns 50,000 shares of the company’s stock, valued at approximately $407,500. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Regulus Therapeutics (NASDAQ:RGLS) traded up 8.75% on Tuesday, hitting $8.58. 428,906 shares of the company’s stock traded hands. Regulus Therapeutics has a 52 week low of $4.70 and a 52 week high of $12.89. The stock’s 50-day moving average is $6.88 and its 200-day moving average is $8.38. The company’s market cap is $358.4 million.

Several analysts have recently commented on the stock. Analysts at TheStreet upgraded shares of Regulus Therapeutics from a “sell” rating to a “hold” rating in a research note to investors on Monday. Separately, analysts at Cowen and Company reiterated an “outperform” rating on shares of Regulus Therapeutics in a research note to investors on Thursday, November 14th. Finally, analysts at FBR & Co. initiated coverage on shares of Regulus Therapeutics in a research note to investors on Wednesday, October 30th. They set an “outperform” rating on the stock. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $14.75.

Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing first-in-class drugs that target microRNAs to treat a range of diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.